Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
figureposted on 2021-02-03, 17:20 authored by Adis journals on behalf of, Shuosha Li, Huabin Hu, Dong Ding, Youwen Zhu, Jin Huang
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.